Impact of radiation dose on recurrence in high-risk prostate cancer patients

被引:2
作者
Deek, Matthew [1 ]
Lilleby, Wolfgang [2 ]
Vaage, Victoria [2 ]
Hole, Knut H. [3 ,4 ]
DeWeese, Theodore [1 ]
Stensvold, Andreas [5 ]
Phuoc Tran [1 ]
Seierstad, Therese [6 ]
机构
[1] Johns Hopkins Univ Hosp, Dept Radiat Oncol, Baltimore, MD 21287 USA
[2] Oslo Univ Hosp, Dept Oncol, Radium Hosp, N-0380 Oslo, Norway
[3] Oslo Univ Hosp, Dept Radiol, Radium Hosp, Oslo, Norway
[4] Univ Oslo, Fac Clin Med, Oslo, Norway
[5] Ostfold Hosp Trust, Dept Oncol, Kalnes, Ostfold, Norway
[6] Oslo Univ Hosp, Dept Res & Dev, Div Radiol & Nucl Med, Oslo, Norway
关键词
Cambridge Risk Classification System; external beam radiation; prostate cancer; recurrence; EXTERNAL-BEAM RADIOTHERAPY; ANDROGEN SUPPRESSION; BRACHYTHERAPY BOOST; THERAPY; DEPRIVATION; TRIAL; MEN; ESCALATION; MORTALITY; DIAGNOSIS;
D O I
10.1002/pros.24059
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Dose escalated radiation therapy (RT) combined with long-term androgen deprivation therapy (ADT) is a standard of care option for men with high-risk and locally advanced prostate cancer (PCa). However, the optimal dose of escalated RT and ADT is not known. Here we assessed the impact of radiation dose and length of ADT on biochemical recurrence in a multi-institutional cohort stratified by the Cambridge prognostic group (CPG). We hypothesized that radiation dose and length of ADT would impact outcome in similar risk groups of our patients. Methods Two-hundred and forty-four patients were included, 132 from Oslo University Hospital, Department of Oncology and 112 from Johns Hopkins Hospital, Department of Radiation Oncology. Biochemical recurrence was defined as prostate-specific antigen (PSA) nadir +2 ng/mL. Time to recurrence was estimated using Kaplan-Meier analysis and when stratified by CPG the log-rank test was used. Cox regression analysis was performed to identify factors associated with risk of recurrence. Site of recurrence was investigated. Results The median follow-up time was 7.4 years. The vast majority (71%) of patients were classified as high-risk (CPG 4) or very high-risk features (CPG 5). Significantly more PSA recurrences occurred in CPG 5 (41%) compared with CPG 4 (25%) (P = .04) and five-year cumulative recurrence-free survival was lower for CPG 4 and 5 (89% and 68%) compared with CPG 1, 2, and 3 (100%, 100%, and 93%). The recurrence-free survival for CPG 5 was significantly higher for prostate irradiation of 80 Gy as compared with 74 Gy (P = .011). For CPG 4 and 5 no local recurrences were detected in patients receiving 80 Gy. On stepwise Cox regression analysis neither age nor length of ADT were independent prognostic factors for recurrence free survival. Conclusion Prostate dose escalation from 74 to 80 Gy decreases risk of recurrence in high-risk PCa. Further studies are needed to identify the optimal combination of ADT and RT.
引用
收藏
页码:1322 / 1327
页数:6
相关论文
共 22 条
[1]   Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991 [J].
Bolla, Michel ;
Maingon, Philippe ;
Carrie, Christian ;
Villa, Salvador ;
Kitsios, Petros ;
Poortmans, Philip M. P. ;
Sundar, Santhanam ;
van der Steen-Banasik, Elzbieta M. ;
Armstrong, John ;
Bosset, Jean-Francois ;
Herrera, Fernanda G. ;
Pieters, Bradley ;
Slot, Annerie ;
Bahl, Amit ;
Ben-Yosef, Rahamim ;
Boehmer, Dirk ;
Scrase, Christopher ;
Renard, Laurette ;
Shash, Emad ;
Coens, Corneel ;
van den Bergh, Alphonsus C. M. ;
Collette, Laurence .
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15) :1748-+
[2]   External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study [J].
Bolla, Michel ;
Van Tienhoven, Geertjan ;
Warde, Padraig ;
Dubois, Jean Bernard ;
Mirimanoff, Rene-Olivier ;
Storme, Guy ;
Bernier, Jacques ;
Kuten, Abraham ;
Sternberg, Cora ;
Billiet, Ignace ;
Lopez Torecilla, Jose ;
Pfeffer, Raphael ;
Cutajar, Carmel Lino ;
Van der Kwast, Theodore ;
Collette, Laurence .
LANCET ONCOLOGY, 2010, 11 (11) :1066-1073
[3]   Radical radiation for localized prostate cancer: Local persistence of disease results in a late wave of metastases [J].
Coen, JJ ;
Zietman, AL ;
Thakral, H ;
Shipley, WU .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (15) :3199-3205
[4]   Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial [J].
Denham, James W. ;
Steigler, Allison ;
Joseph, David ;
Lamb, David S. ;
Spry, Nigel A. ;
Duchesne, Gillian ;
Atkinson, Chris ;
Matthews, John ;
Turner, Sandra ;
Kenny, Lizbeth ;
Tai, Keen-Hun ;
Gogna, Nirdosh Kumar ;
Gill, Suki ;
Tan, Hendrick ;
Kearvell, Rachel ;
Murray, Judy ;
Ebert, Martin ;
Haworth, Annette ;
Kennedy, Angel ;
Delahunt, Brett ;
Oldmeadow, Christopher ;
Holliday, Elizabeth G. ;
Attia, John .
RADIOTHERAPY AND ONCOLOGY, 2015, 115 (03) :301-307
[5]   THE EFFECT OF LOCAL-CONTROL ON METASTATIC DISSEMINATION IN CARCINOMA OF THE PROSTATE - LONG-TERM RESULTS IN PATIENTS TREATED WITH I-125 IMPLANTATION [J].
FUKS, Z ;
LEIBEL, SA ;
WALLNER, KE ;
BEGG, CB ;
FAIR, WR ;
ANDERSON, LL ;
HILARIS, BS ;
WHITMORE, WF .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1991, 21 (03) :537-547
[6]   The Cambridge Prognostic Groups for improved prediction of disease mortality at diagnosis in primary non-metastatic prostate cancer: a validation study [J].
Gnanapragasam, V. J. ;
Bratt, O. ;
Muir, K. ;
Lees, L. S. ;
Huang, H. H. ;
Stattin, P. ;
Lophatananon, A. .
BMC MEDICINE, 2018, 16
[7]   Improving clinical prognostic stratification models for men with prostate cancer: a practical step closer to more individualized care without added costs [J].
Gnanapragasam, Vincent J. ;
Warren, Anne Y. .
BJU INTERNATIONAL, 2017, 119 (03) :366-367
[8]   Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study [J].
Hofman, Michael S. ;
Lawrentschuk, Nathan ;
Francis, Roslyn J. ;
Tang, Colin ;
Vela, Ian ;
Thomas, Paul ;
Rutherford, Natalie ;
Martin, Jarad M. ;
Frydenberg, Mark ;
Shakher, Ramdave ;
Wong, Lih-Ming ;
Taubman, Kim ;
Lee, Sze Ting ;
Hsiao, Edward ;
Roach, Paul ;
Nottage, Michelle ;
Kirkwood, Ian ;
Hayne, Dickon ;
Link, Emma ;
Marusic, Petra ;
Matera, Anetta ;
Herschtal, Alan ;
Iravani, Amir ;
Hicks, Rodney J. ;
Williams, Scott ;
Murphy, Declan G. .
LANCET, 2020, 395 (10231) :1208-1216
[9]   Routine pelvic MRI using phased-array coil for detection of extraprostatic tumour extension: accuracy and clinical significance [J].
Hole, Knut Hakon ;
Axcrona, Karol ;
Lie, Agnes Kathrine ;
Vlatkovic, Ljiljana ;
Geier, Oliver Marcel ;
Brennhovd, Bjorn ;
Knutstad, Kjetil ;
Olsen, Dag Rune ;
Seierstad, Therese .
EUROPEAN RADIOLOGY, 2013, 23 (04) :1158-1166
[10]   Ten-year follow-up of radiation therapy oncology group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer [J].
Horwitz, Eric M. ;
Bae, Kyounghwa ;
Hanks, Gerald E. ;
Porter, Arthur ;
Grignon, David J. ;
Brereton, Harmar D. ;
Venkatesan, Varagur ;
Lawton, Colleen A. ;
Rosenthal, Seth A. ;
Sandler, Howard M. ;
Shipley, William U. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15) :2497-2504